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Changes of Circulating Transforming Growth Factor-1
Level During Radiation Therapy Are Correlated with the
Prognosis of Locally Advanced Non-small Cell Lung Cancer
Lujun Zhao, MD, PhD,*† Wei Ji, MD, PhD,*‡ Li Zhang, MD, PhD,*§ Guangfei Ou, MD, PhD,*
Qinfu Feng, MD,* Zongmei Zhou, MD,* Mingfang Lei, MSc,* Weizhi Yang, MD,*
and Luhua Wang, MD*
Introduction: We hypothesized that plasma transforming growth
factor-1 (TGF-1) level and its dynamic change are correlated
with the prognosis of locally advanced non-small cell lung cancer
(NSCLC) treated with radiation therapy (RT).
Methods: Patients with stage IIIA or IIIB NSCLC treated with RT
with or without chemotherapy were eligible for this study. Platelet
poor plasma was collected from each patient within 1 week before
RT (pre-RT) and at the 4th week during RT (during-RT). TGF-1
level was measured with enzyme-linked immunosorbent assay. The
primary end point was overall survival (OS) and the secondary end
point was progression-free survival (PFS). Kaplan-Meier and Cox
regression were used for risk factor evaluation.
Results: A total of 65 patients were eligible for the study. The
median OS and PFS were 17.7 and 13.7 months, respectively. In
univariate analysis, performance status, weight loss, radiation dose,
and TGF-1 ratio (during-RT/pre-RT TGF-1 level) were all sig-
nificantly correlated with OS. In the multivariate analysis, perfor-
mance status, radiation dose, and TGF-1 ratio were still signifi-
cantly correlated with OS. The median OS was 30.7 months for
patients with TGF-1 ratio 1 versus 13.3 months for those with
TGF-1 ratio more than 1 (p  0.0029); and the median PFS was
16.8 months versus 7.2 months, respectively (p  0.010).
Conclusions: In locally advanced NSCLC, the decrease of TGF-1
level during RT is correlated with favorable prognosis.
Key Words: Non-small cell lung cancer, Radiation therapy, Trans-
forming growth factor-1, Prognosis.
(J Thorac Oncol. 2010;5: 521–525)
There are many obstacles to the improvement of prognosisin locally advanced non-small cell lung cancer (NSCLC).
Among those factors, two factors were studied most exten-
sively, one is the limitation to the escalation of radiation dose
and the concurrent administration of chemotherapy because
of radiation-induced lung toxicities (RILT),1–5 and the other
is the immune escape of cancer cells partly due to various
cytokines secreted by cancer cells and its surrounding tis-
sues.6 Transforming growth factor-1 (TGF-1) plays an
important role both in RILT7–9 and in the immune escape of
cancer cells.10–12
It has been reported that TGF-1 level in lung cancer
tissues13–16 or in the plasma of patients with lung cancer was
correlated with the prognosis of the disease.17,18 However, to
the best of our knowledge, there is no study published so far
reporting the relationship between the plasma TGF-1 level
or its dynamic changes during the fractionated radiation
therapy (RT) and the overall survival (OS) in locally ad-
vanced NSCLC. The purpose of this study was to evaluate
whether the plasma TGF-1 level before RT and its change




This was a retrospective study, which was approved by
our institutional review board. All data were from a prospec-
tive study that was performed to evaluate the correlations
between circulating cytokine levels (including TGF-1) and
the risk of RILT in patients with unresectable or medically
inoperable NSCLC. The inclusion criteria of the prospective
trial have been described in detail previously.19 Briefly,
patients must have histopathologically confirmed stage I–III
NSCLC, with a Karnofsky performance status more than 60,
with an expected survival duration more than 6 months, and
with forced expiratory volume in the first 1 second more than
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50% of the predictive value. Only patients with stage III
NSCLC with TGF-1 measurement available both before RT
and at the 4th week during RT were eligible for this retro-
spective study. The disease stage was reassessed for all
patients based on 2002 American Joint Committee on Cancer
tumor, node, metastasis classification system.
Treatment Regimen
RT was given by a consistent three-dimensional con-
formal technique. Treatment-planning computed tomography
(CT) scans were performed with patients breathing comfort-
ably while lying supine in the treatment position with proper
immobilization. The gross tumor volume (GTV) included the
primary tumor, any hilar or mediastinal lymph nodes with a
short-axis diameter of at least 1 cm on CT or fluorodeoxy-
glucose avidity on fluorodeoxyglucose positron emission to-
mography, and any abnormal findings detected on bronchos-
copy or mediastinoscopy. The clinical target volume (CTV)
was uniformly created by expanding the GTV by a 0.5 to 1.0
cm margin. Hilar, mediastinal, and supraclavicular nodal
regions that appeared to be uninvolved by CT or positron
emission tomography were not purposely included in the
CTV. The planning target volume was created by expanding
the CTV by a minimum of 0.5 cm for setup error. A lung
dose-volume histogram was generated with inclusion of both
right and left lungs with subtraction of GTV. Tissue inhomo-
geneity correction was applied for all plans.
Chemotherapy was given before, during, and/or after
RT. When chemotherapy was given sequentially with RT,
platinum-based doublets (carboplatin/cisplatin combined
with vinorelbine, paclitaxel, or gemcitabine) were the com-
monly used regimens, for 3 to 4 cycles before or after RT.
When chemotherapy was given concurrently, the combina-
tion of carboplatin and paclitaxel were commonly used, with
the carboplatin dose of area under the curve  2 and the
paclitaxel dose of 45 mg/m2, once a week, for 4 to 6 weeks.
Sample Collection and TGF-1 Measurement
Blood samples were collected with K2EDTA as the
anticoagulant within 1 week before RT (pre-RT) and at the
4th week during RT (during-RT) from all patients. Blood
samples from 26 healthy volunteers were also collected as
normal controls. The samples were kept on ice for no longer
than 1 hour before centrifuging at 1000 g for 15 minutes. The
upper one-third of the supernatants were collected and stored
at 70°C. Such processing generates platelet-rich plasma,
thus the samples were recentrifuged at 10,000 g for 30
minutes before measurement of TGF-1. Plasma TGF-1
levels were measured with enzyme-linked immunosorbent
assay using human TGF-1 Quantikine Kit (R&D Systems
Inc., Minneapolis, MN).
Study End Points and Statistical Analysis
Patients were seen weekly during RT and then, after the
first follow-up at 1 month after RT, every 3 months for 2
years and every 6 months until the patient was dead. The
primary end point was OS, which was defined as the duration
between the start of RT and the date of death. The second end
point was progression-free survival (PFS), which was defined
as the duration between the start of RT and the date of disease
progression. Data were considered as right censored for PFS
if patients died without evidence of disease progression.
TGF-1 ratio, which was defined as the ratio of during-RT
TGF-1 level compared with its pre-RT level, was used to
present the dynamic change of circulating TGF-1 level. As
used previously in our study,9 changes of plasma TGF-1
level during fractionated RT were divided into two groups:
TGF-1 ratio more than 1 and TGF-1 ratio 1, for the
calculation of OS and PFS.
Cox proportional hazard model was used to estimate
the impacts of TGF-1 level and clinical factors on OS and
PFS. The Kaplan-Meier method and log-rank test were used
to compare the OS and PFS in different groups. All the data
were presented as mean SD unless otherwise specified. All
p values were two-sided.
RESULTS
Clinical Characteristics
A total of 139 patients were included in the initial
prospective study. Seventy-four patients were excluded from
this study for the following reasons: 27 patients were identi-
fied with stage I–II disease, 8 patients were identified with
stage IV disease, and 39 patients had only pre-RT TGF-1
measured. The 65 remaining patients were included in the
final analysis. The clinical characteristics of the eligible
patients and the treatments given to those patients are listed in
Table 1.
TGF-1 Level Measurement
The mean TGF-1 level was 4.8 5.6 ng/ml in pre-RT
patients, which was significantly higher than in normal con-
trols (0.5  0.2 ng/ml, p  0.001). No significant correlation
was found between pre-RT TGF-1 level and any of the
following factors: smoking status (p 0.366), histopathology
TABLE 1. Clinical Characteristics and Treatment Regimens
Parameters Value





Weight loss 5% (yes/no) 21/44
Ever smoking (yes/no) 49/16
Chemotherapy (yes/no) 55/10
Concurrent chemoradiotherapy (yes/no) 41/24
Radiation dose, Gy, median (range) 60 (45–70)
V20 (%) 25.5%  5.9%
Mean lung dose (Gy) 15.3  4.2
Pre-RT TGF-1 level (ng/ml) 4.8  5.6
During-RT TGF-1 level (ng/ml) 3.7  3.4
TGF-1 ratio (1/1) 27/38
KPS, Kamofsky performance status; V20, the percentage of the whole lung which
received a dose more than 20 Gy; RT, Radiation therapy; TGF-1, transforming growth
factor 1; SCC, squamous cell carcinoma; AC, adenocarcinoma; TGF-1 ratio, the ratio
of during-RT TGF-1 level compared with its pre-RT level.
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(p  0.295), stage of disease (stage IIIA versus stage IIIB,
p  0.288), and GTV (p  0.124). At the 4th week during
RT, the mean level of plasma TGF-1 of the entire group was
not significantly different from its pre-RT level (3.7  3.4
ng/ml versus 4.8  5.6 ng/ml, respectively, paired t test, p 
0.116). Thirty-eight patients had decreased TGF-1 level and
the other 27 patients had increased TGF-1 level.
Factors Associated with OS and PFS
The median OS and PFS for the entire group of patients
were 17.7 months (95% confidential interval [CI]: 10.8–24.5
months) and 13.7 months (95% CI: 8.0–19.4 months), re-
spectively (Fig. 1). In univariate analysis, performance status,
weight loss, radiation dose, and TGF-1 ratio were all sig-
nificantly correlated with OS, and only weight loss, dur-
ing-RT TGF-1 level, and TGF-1 ratio were significantly
correlated with PFS; radiation dose was marginally correlated
with PFS (Table 2). When performance status, weight loss,
radiation dose, and TGF-1 ratio were included together into
the multivariate Cox regression analysis, it was found that
only performance status, radiation dose, and TGF-1 ratio
were significantly correlated with OS, and only weight loss
and TGF-1 ratio were significantly correlated with PFS
(Table 3).
The median OS was 30.7 months (95% CI: 15.9–45.5
months) for patients with TGF-1 ratio 1 (n  38) versus
13.3 months (95% CI: 10.9–15.7 months) for those with
TGF-1 ratio more than 1 (n  27), and the 3-year OS was
46.7% versus 19.8%, respectively (Fig. 2, p  0.003). The
corresponding median PFS were 16.8 months (95% CI:
12.5–21.2 months) and 7.2 months (95% CI: 6.2–8.2
months), and the 3-year PFS were 30.5% and 0.0%, respec-
tively (Fig. 3, p  0.010).
In patients with low pre-RT TGF-1 level, the change of
TGF-1 level is more “upside potential” than “downside poten-
tial,” and vice versa. To clarify this issue, all the patients were
divided into 2 groups for further analysis: those with pre-RT
TGF-1 level 3 ng/ml, the median level of the pre-RT
TGF-1, and those with TGF-1 level more than 3 ng/ml. In
patients with low pre-RT TGF-1 level, the median OS was
30.7 months (95% CI: unavailable) for those with TGF-1
ratio 1 (n  16) versus 13.3 months (95% CI: 10.7–15.9
months) for those with TGF-1 ratio more than 1 (n  17),
and the 3-year OS was 45.1% versus 11.8%, respectively
(p  0.001). The median PFS was 17.9 months (95% CI:
7.7–28.1 months) versus 6.7 months (95% CI: 5.0–8.3
months), and the 3-year PFS was 31.6% versus 0.0%, respec-
tively (p  0.003). In patients with high pre-RT TGF-1
level, the median OS was 22.2 months (95% CI: 8.4–35.9
months) for those with TGF-1 ratio1 (n 22) versus 11.7
months (95% CI: 7.0–16.4 months) for those with TGF-1
ratio more than 1 (n  10), and the 3-year OS was 36.4%
versus 12.5%, respectively (p 0.064). The median PFS was
13.7 months (95% CI: 2.7–24.7 months) versus 7.3 months
(95% CI: 1.9–12.6 months), and the 3-year PFS was 19.3%
versus 0.0%, respectively (p  0.048).
As reported previously, elevation of TGF-1 dur-
ing-RT is significantly correlated with RILT.7,8 To clarify the
confounding effect of RILT, another analysis was made with
patients who experienced grade 3 and above RILT excluded.
In this selected group of patients, the median OS was 36.6
FIGURE 1. The overall survival (OS) and progression-free
survival (PFS) for the whole group of patients.









0.712 0.520 0.710 0.472
Age 1.016 0.224 1.005 0.728
KPS 0.930 0.019 0.965 0.212
Weight loss 5% 2.073 0.023 2.245 0.009
Ever smoking 1.561 0.241 0.994 0.987
Histopathology — 0.497 — 0.733
Stage IIIB compared with
stage IIIA
1.112 0.771 1.394 0.338
Radiation dose 0.911 0.001 0.949 0.064
Administration of
chemotherapy
0.791 0.573 1.535 0.333
Pre-RT TGF-1 level 1.021 0.520 1.041 0.152
During-RT TGF-1
level
1.032 0.469 1.091 0.020
TGF-1 ratio 1.422 0.002 1.380 0.004
KPS, Kamofsky performance status; RT, radiation therapy; TGF-1, transforming
growth factor 1; OR, odds ratio; OS, overall survival; PFS, progression-free survival;
TGF-1 ratio, the ratio of during-RT TGF-1 level compared with its pre-RT level.
TABLE 3. Factors Correlated with OS and PFS in






KPS 0.933 0.042 0.978 0.489
Weight loss 5% 1.630 0.126 2.153 0.015
Radiation dose 0.918 0.002 0.954 0.112
TGF-1 ratio 1.279 0.042 1.374 0.006
KPS, Kamofsky performance status; TGF-1, transforming growth factor 1; OR,
odds ratio; OS, overall survival; PFS, progression-free survival; TGF-1 ratio, the ratio
of during-RT TGF-1 level compared with its pre-RT level.
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months (95% CI: 21.1–52.0 months) and the 3-year OS was
43.5% in patients with TGF-1 ratio 1, and they were 13.6
months (95% CI: 10.7–16.5 months) and 24.5% in those with
TGF-1 ratio more than 1, respectively (p  0.010). The
corresponding PFS were 17.2 months (95% CI: 14.7–19.6
months) and 24.9% versus 7.2 months (95% CI: 6.2–8.2
months) and 0.0%, respectively, (p  0.008).
DISCUSSION
As reported in the literatures,20,21 this retrospective
study found that performance status, weight loss, and radia-
tion dose are all important prognostic factors for OS in
patients with locally advanced NSCLC. Most importantly,
this study suggested that patients with decreased circulating
TGF-1 level at the 4th week during RT compared with its
baseline level may have a favorable prognosis, with longer
OS and PFS.
However, in this study, disease stage and the adminis-
tration of chemotherapy failed to show significant influence
on OS and PFS. This may be at least partly due to that only
patients with stage III disease were included, which weak-
ened the prognosis value of disease stage, and that only 10
patients received RT alone, which made it impossible to get
a reasonable comparison with combined treatment modality.
TGF-1 plays an important role in the development and
progression of NSCLC. Almost all human tumors overpro-
duce TGF-1, whose autocrine and paracrine actions pro-
mote tumor cell invasiveness and metastasis.22 TGF-1 also
suppresses proliferation and differentiation of lymphocytes
including cytolytic T cells, natural killer cells, and macro-
phages, thus preventing immune surveillance of the develop-
ing tumor.22 Studies on specimens from patients with NSCLC
showed that the overall prognosis is significantly poorer for
patients showing positive TGF-1 expression in tumors,13,14
and this may be due to the immune suppression effect of
TGF-1 through CD4 CD25 regulatory T cells.16
Circulating TGF-1 level was also reported to be cor-
related with the prognosis of NSCLC. In 1999, Kong et al.18
reported that the pre-RT plasma TGF-1 level was signifi-
cantly higher in patients with lung cancer than in normal
controls, and it was significantly higher in patients with
disease at the last follow-up compared with that in the no
evidence of disease group. In this study, we also found that
patients with NSCLC had significantly higher TGF-1 level
than normal controls. Most importantly, for the first time, we
found that patients with decreased circulating level of
TGF-1 at the 4th week during RT compared with its
baseline level may have a prolonged overall survival. Further
analysis demonstrated that no matter in patients with higher
pre-RT TGF-1 level or in patients with lower pre-RT level,
the decrease of TGF-1 level during RT all correlated with an
improved prognosis. Our results also suggested that lower
absolute level of circulating TGF-1 during RT may predict
an improved tumor control. Decreased tumor burden may
contribute to the decreased level of TGF-1 and this may
result in an improved antitumor immunity. Much work needs
to be done to further clarify the underlying mechanisms.
It was reported that increased circulating TGF-1 level
correlated with increased risk of RILT.7,23 This may contrib-
ute to the increased risk of death. However, in this study, the
change of circulating TGF-1 level was independently cor-
related not only with the OS but also with the PFS. Further-
more, even when patients with grade 3 and above RILT were
excluded, those with decreased level of TGF-1 still had a
favorable prognosis. These results suggested that TGF-1
level plays an important role in the progression of NSCLC
and the decrease of circulating TGF-1 level during RT may
predict a favorable prognosis. Much research needs to be
done to further clarify the underlying mechanism.
It should be noted that this is a retrospective study and
suffers the pitfalls of all such kind of studies. The chemo-
therapy given to these patients were inconsistent, and the
radiation dose varied from 45 to 70 Gy. All these confound-
ing factors might interfere with the conclusions of this study
and should be taken into consideration.
FIGURE 2. Difference in overall survival between patients
with transforming growth factor-1 (TGF-1) ratio (during-
RT/pre-RT TGF-1 level) 1 (n  38) and those with TGF-1
ratio 1 (n  27) (p  0.003).
FIGURE 3. Difference in progression-free survival between
patients with transforming growth factor-1 (TGF-1) ratio
(during-RT/pre-RT TGF-1 level) 1 (n  38) and those with
TGF-1 ratio 1 (n  27) (p  0.010).
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In summary, the results of this retrospective study
suggest that TGF-1 level is significantly higher in locally
advanced NSCLC than in healthy controls and the decrease of
circulating TGF-1 level at the 4th week during RT may
predict a prolonged OS and PFS. The findings need to be
validated and the underlying mechanism and the potential of
TGF-1 signal pathway as a novel target for the treatment of
locally advanced NSCLC are worthy of further study.
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